Table 3.
Baseline Efficacy Measures From 4 Studies of Duloxetine for the Treatment of Fibromyalgia
| Duloxetine |
Placebo |
|||
| Efficacy Measure (score range) | n | Mean (SD) | n | Mean (SD) |
| Brief Pain Inventory score (0–10) | ||||
| 24-h Average pain severity | 774 | 6.4 (1.6) | 526 | 6.4 (1.6) |
| Least pain severity | 774 | 7.5 (1.7) | 526 | 7.5 (1.7) |
| Worst pain severity | 775 | 4.8 (2.1) | 526 | 4.9 (2.1) |
| Pain severity right now | 775 | 6.3 (2.1) | 526 | 6.3 (2.1) |
| Pain interference | 775 | 5.7 (2.2) | 526 | 5.7 (2.1) |
| FIQ total score (0–80) | 756 | 50.9 (12.8) | 513 | 51.6 (12.2) |
| CGI-S score (0–7) | 744 | 4.1 (0.9) | 506 | 4.1 (1.1) |
| HDRS-17 score (0–52) | 620 | 10.4 (6.0) | 390 | 10.3 (5.9) |
Abbreviations: CGI-S = Clinical Global Impressions-Severity of Illness scale, FIQ = Fibromyalgia Impact Questionnaire, HDRS-17 = 17-item Hamilton Depression Rating Scale.